TITLE

Frequency of Thyroid Dysfunctions during Interferon Alpha Treatment of Single and Combination Therapy in Hepatitis C Virus-Infected Patients: A Systematic Review Based Analysis

AUTHOR(S)
Nair Kesavachandran, Chandrasekharan; Haamann, Frank; Nienhaus, Albert
PUB. DATE
February 2013
SOURCE
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Thyroid dysfunction is the commonest endocrinopathy associated with HCV infection due to interferon-based treatment. This comprehensive and systematic review presents the available evidence for newly developed thyroid antibodies and dysfunctions during interferon treatment (both single and combination) in HCV patients. Methodology/Principal Findings: This systematic review was conducted in accordance with the PRISMA guidelines. The data generated were used to analyze the risk for thyroid dysfunctions during interferon (IFN) treatment in HCV patients. There was a wide range in the incidence of newly developed thyroid dysfunctions and thyroid antibodies in HCV patients during IFN treatment (both single and combination). The wide range of incidence also denoted the possibility of factors other than IFN treatment for thyroid-related abnormalities in HCV patients. These other factors include HCV viral factors, genetic predisposition, environmental factors, and patho-physiological factors. Variations in IFN dosage, treatment duration of IFN, definition/criteria followed in each study for thyroid dysfunction and irregular thyroid function testing during treatment in different studies influence the outcome of the single studies and jeopardise the validity of a pooled risk estimate of side effects of thyroid dysfunction. Importantly, reports differ as to whether the thyroid-related side effects disappear totally after withdrawal of the IFN treatment. Conclusions/Significance: The present review shows that there is a wide range in the incidence of newly developed thyroid dysfunctions and thyroid antibodies in IFN treated HCV patients. This is a comprehensive attempt to collate relevant data from 56 publications across several nations about IFN (both mono and combination therapy) related thyroid dysfunction among HCV patients. The role of each factor in causing thyroid dysfunctions in HCV patients treated with IFN should be analyzed in detail in future studies, for a better understanding of the problem and sounder clinical management of the disease.
ACCESSION #
87623715

 

Related Articles

  • Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice. Niu Shi; Nobuhiko Hiraga; Michio Imamura; Hayes, C. Nelson; Yizhou Zhang; Kosaka, Keiichi; Okazaki, Akihito; Murakami, Eisuke; Tsuge, Masataka; Abe, Hiromi; Aikata, Hiroshi; Takahashi, Shoichi; Tateno-Mukaidani, Chise; Yoshizato, Katsutoshi; Matsui, Hirotaka; Kanai, Akinori; Inaba, Toshiya; McPhee, Fiona; Min Gao; Chayama, Kazuaki // Gut;Jul2013, Vol. 62 Issue 7, p1055 

    The article presents a study related to effect of combining NS5A replication complex inhibitor (RCI), NS3 protease inhibitor and NS5B polymerase inhibitor on different genotypes of hepatitis C virus in human hepatocyte chimeric mice. It states that direct and ultra-deep sequencing was performed...

  • Sequencing of the Hepatitis C Virus: A Systematic Review. Jacka, Brendan; Lamoury, Francois; Simmonds, Peter; Dore, Gregory J.; Grebely, Jason; Applegate, Tanya // PLoS ONE;Jun2013, Vol. 8 Issue 6, p1 

    Since the identification of hepatitis C virus (HCV), viral sequencing has been important in understanding HCV classification, epidemiology, evolution, transmission clustering, treatment response and natural history. The length and diversity of the HCV genome has resulted in analysis of certain...

  • Natural Killer KIR3DS1 Is Closely Associated with HCV Viral Clearance and Sustained Virological Response in HIV/HCV Patients. Rivero-Juarez, Antonio; Gonzalez, Rafael; Camacho, Angela; Manzanares-Martin, Barbara; Caruz, Antonio; Martinez-Peinado, Antonio; Torre-Cisneros, Julian; Pineda, Juan A.; Peña, José; Rivero, Antonio // PLoS ONE;Apr2013, Vol. 8 Issue 4, p1 

    Aim: To evaluate the influence of the presence of the killer cell immunoglobulin-like receptor (KIR) 3DS1 on HCV treatment response in HIV/HCV genotype 1 co-infected patients Methods: HIV/HCV co-infected patients were included. KIR3DS1, their specific HLA-B ligands and IL28B gene were...

  • Deep Sequencing Analysis of HCV NS3 Resistance-Associated Variants and Mutation Linkage in Liver Transplant Recipients. Kirst, Mariana E.; Li, Eric C.; Wang, Cindy X.; Dong, Hui-Jia; Liu, Chen; Fried, Michael W.; Nelson, David R.; Wang, Gary P. // PLoS ONE;Jul2013, Vol. 8 Issue 7, p1 

    Viral variants with decreased susceptibility to HCV protease inhibitors (PIs) occur naturally and preexist at low levels within HCV populations. In patients failing PI monotherapy, single and double mutants conferring intermediate to high-level resistance to PIs have been selected in vivo. The...

  • Prevalencia de anticuerpos contra el virus de hepatitis C en unidades de diálisis de Cali-Colombia. Ramírez, Roberto; Fernández, Julián; Guevara, Juan Guillermo; Valderrama, Luis Alfonso; Castro, Adolfo León; Álvarez, Javier Arango; Holguín, R. Jaime // Revista Colombiana de Gastroenterología;Mar2010, Vol. 25 Issue 1, p14 

    The prevalence of anti-HCV antibodies among patients on dialysis is consistently higher than in healthy populations, suggesting that dialysis patients may be at higher risk of acquiring HCV infection. The aim of our study was to determinate the prevalence of anti-HCV antibodies in patients whom...

  • NEW APPROACHES IN THE THERAPY OF HEPATITIS C IN DIALYSIS PATIENTS. Sikole, A.; Dzekova, P.; Asani, A.; Amitov, V.; Selim, Gj.; Gelev, S.; Polenakovic, M. // Contributions of Macedonian Academy of Sciences & Arts;2008, Vol. 29 Issue 2, p155 

    Patients with renal disease are at increased risk of acquiring hepatitis C virus (HCV) infection because of their frequent exposure to blood from transfusions or exposure to HCV-contaminated medical equipment during hemodialysis. The prevalence of anti-HCV antibodies among hemodialysis patients...

  • Diversity of Killer Cell Immunoglobulin-Like Receptor (KIR) Genotypes and KIR2DL2/3 Variants in HCV Treatment Outcome. Vidal-Castiñeira, Jose Ramón; López-Vázquez, Antonio; Martínez-Borra, Jesús; Martínez-Camblor, Pablo; Prieto, Jesús; López-Rodríguez, Rosario; Sanz-Cameno, Paloma; de la Vega, Juan; Rodrigo, Luis; Pérez-López, Rosa; Pérez-Álvarez, Ramón; López-Larrea, Carlos // PLoS ONE;Jun2014, Vol. 9 Issue 6, p1 

    The aim of this study was to analyse the distribution of KIR haplotypes and the KIR2DL2/3 alleles in chronic HCV-infected patients in order to establish the influence on the response to pegylated interferon plus ribavirin classical treatment. The alleles study of previously associated KIR2DL2/3...

  • Variation analysis of E1 and E2 in HCV subtypes. Cheng, Xue-Di; Xu, Hua-Feng; Wei, Xue-Mei; Zhou, Hai-Zhou // Archives of Virology;Oct2015, Vol. 160 Issue 10, p2479 

    Pegylated interferon and ribavirin combination therapy effectively suppresses viral replication in 50 %-60 % of hepatitis C virus (HCV)-infected patients. However, HCV-infected patients often display varied responses to therapy, and strains of subtype lb (the most widespread HCV subtype...

  • HCV genotype 4 patients achieved SVR12 with triple therapy.  // Infectious Disease News;Jun2014, Vol. 27 Issue 6, p32 

    An abstract of the article "HCV genotype 4 patients achieved SVR12 with triple therapy," by Tarek Hassanein and colleagues is presented.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics